Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7051562 | 0.84 | GABRA1 (0.33) | GABRA1GABRB2MEN1MAPTMAPK1 | |
| SCHEMBL2536793 | 0.81 | GABRA1 (0.36) | GABRA1GABRB2 | |
| SCHEMBL703794 | 0.76 | GABRA1 (0.33) | GABRA1GABRB2 | |
| SCHEMBL10588785 | 0.73 | GABRA1 (0.32) | GABRA1GABRB2 | |
| SCHEMBL27431762 | 0.72 | — | — | |
| SCHEMBL21194014 | 0.72 | — | — | |
| SCHEMBL458035 | 0.72 | — | — | |
| SCHEMBL5822189 | 0.72 | GABRA1 (0.50) | GABRA1GABRB2MEN1MAPTKMT2A | |
| SCHEMBL6594676 | 0.72 | GABRA1 (0.33) | GABRA1GABRB2 | |
| SCHEMBL2301007 | 0.72 | ALDH1A1 (0.43) | GABRA1GABRB2MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718769-B2 | Tri-peptide hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2010-05-18 | — | — | US | claimed |
| US-7601709-B2 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | claimed |
| US-7273851-B2 | Tri-peptide hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2007-09-25 | — | — | US | claimed |
| US-20070161575-A1 | Tri-peptide hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2007-07-12 | — | — | US | claimed |
| WO-2004113365-A9 | HEPATITIS C SERINE PROTEASE TRI-PEPTIDE INHIBITORS | — | 2006-03-23 | — | — | WO | claimed |
| US-20050261200-A1 | Tri-peptide hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2005-11-24 | — | — | US | claimed |
| US-20050153877-A1 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | claimed |
| WO-2004113365-A2 | HEPATITIS C SERINE PROTEASE TRI-PEPTIDE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2004-12-29 | — | — | WO | claimed |
| US-8124584-B2 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-7718769-B2 | Tri-peptide hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-20090304629-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | MIAO ZHENWEI | 2009-12-10 | — | — | US | disclosed |
| US-7601709-B2 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-7273851-B2 | Tri-peptide hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-20070161575-A1 | Tri-peptide hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| WO-2004113365-A9 | HEPATITIS C SERINE PROTEASE TRI-PEPTIDE INHIBITORS | — | 2006-03-23 | — | — | WO | disclosed |
| US-20050261200-A1 | Tri-peptide hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2005-11-24 | — | — | US | disclosed |
| US-20050153877-A1 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| WO-2004113365-A2 | HEPATITIS C SERINE PROTEASE TRI-PEPTIDE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261200-A1 | Tri-peptide hepatitis C serine protease inhibitors | PRSS1, VIP, HPN | GABRA1 4754/4885GABRB2 4739/4885MEN1 3885/4885 |
| US-20050153877-A1 | Macrocyclic hepatitis C serine protease inhibitors | PRSS1, SPINT2, TMPRSS4 | GABRA1 4792/4885GABRB2 4790/4885MEN1 4037/4885 |
| US-20090304629-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, TMPRSS4 | GABRA1 4803/4885GABRB2 4781/4885MEN1 4019/4885 |
| US-20070161575-A1 | Tri-peptide hepatitis C serine protease inhibitors | PRSS1, VIP, HPN | GABRA1 4754/4885GABRB2 4739/4885MEN1 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.